HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
about
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesMechanisms regulating resistance to inhibitors of topoisomerase II.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancerAdjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinomaXenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancerAmplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.TOP2A gene copy number change in breast cancer.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Triple-negative breast cancer: making the most of a misnomer.Relapsed triple-negative breast cancer: challenges and treatment strategies.Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?The role of anthracyclines in the treatment of early breast cancer.Optimal adjuvant chemotherapy in breast cancer: selection of agents.Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancersTopoisomerase expression and amplification in solid tumours: Analysis of 24,262 patientsAnalysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.
P2860
Q28079118-B0105919-1095-4940-8357-77FE92AF7663Q33698446-0916236D-63A8-49D0-8157-BF7F263C9B69Q33820233-8703FB00-727F-4B6A-BE40-B2774A68D40EQ33914753-74902F30-F290-48B7-8EDF-6B30FB9FD225Q33995239-3B97586B-CAA4-4035-994F-CC03D28651FBQ34023749-738CB870-1999-43C3-A006-DD929AA16B37Q34361770-70DFF1F4-B59B-43B4-8F05-2EB96DE0FD68Q34417532-5A6B5C9E-D6FD-421E-A159-8C5890D7EA90Q34620545-B8A02ED5-AA37-46DF-9E66-0721F118A167Q34640536-C396ABD9-337E-4AC2-A2C9-78BD48A8AB36Q34655579-2D12D787-041C-4980-B7A2-A575F1FB7950Q35807180-912D7DFA-888C-4485-8F3A-3AE28EC60C61Q35921206-E922D5CB-0929-4AE6-8220-886E257C9CA3Q36045385-FA7E9A1D-8069-4B54-A978-04A771EBE108Q36300973-EEAE24F1-20D3-4006-A815-23C44266C9ADQ36349584-A0E88F42-3E73-49D3-9C75-33E6B81EA9E8Q36387794-90D09F95-6DC6-4EF7-B409-E54031476899Q36402262-6436EAF4-CB6C-4BCD-A138-22AD999187BAQ36640582-DF11A162-7067-429D-8B74-D37B74BD64DCQ36903127-A7563354-FE14-49B9-9365-9530104800E4Q37095799-706DDB8C-B690-4466-AAC6-DBB948E0DAD1Q37247163-5126E89F-4421-4C75-8584-FB29DAF1B50BQ37295329-98C3B2FC-8D0C-4AE5-8BF7-D25EE3374177Q37295618-478EF94B-BBF9-4213-AA2F-501E064AF0DCQ37376754-060617E8-9A0D-467D-BB16-F0D7D0FA2038Q37413146-36618B87-08BA-4D13-A37B-A24A544B1057Q37532636-9FC57222-05F2-43F6-9551-732515F4DAB5Q37606324-579E4A67-787F-4C3C-945B-F0ADF3869D54Q37716023-A5D34839-1F76-40D6-B622-1A0AB964AF5CQ37989074-314F6947-8EC9-47FB-AC1A-D85AA22E18E2Q38004606-6FAF1071-73B8-468E-BE7C-8E6717DB349BQ38120666-A90A1EAA-C42F-4CE9-A180-512BBC3656D3Q38195674-64D91504-0ED6-42C7-A576-1D9D455C28B5Q38207452-8ABD2892-E435-4567-9972-7C4AC784E7DCQ38235713-347648F7-EE3F-4F33-97A0-B953A4B198FCQ38387376-922D21B2-32B9-4E0D-8244-4FDCA3F7344AQ38669870-F6B0E78E-04E1-4593-9A84-15512EED5E05Q39308117-B1AEEF76-2552-4BF5-8CDF-88EDC9D347B7Q39336778-3B15BB1F-7F04-4A29-A147-8F4BAE4BB1B0Q39528312-113A967F-85FE-44A9-9AEA-083A63DC5825
P2860
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HER2 and TOP2A as predictive m ...... is of individual patient data.
@ast
HER2 and TOP2A as predictive m ...... is of individual patient data.
@en
HER2 and TOP2A as predictive m ...... is of individual patient data.
@nl
type
label
HER2 and TOP2A as predictive m ...... is of individual patient data.
@ast
HER2 and TOP2A as predictive m ...... is of individual patient data.
@en
HER2 and TOP2A as predictive m ...... is of individual patient data.
@nl
prefLabel
HER2 and TOP2A as predictive m ...... is of individual patient data.
@ast
HER2 and TOP2A as predictive m ...... is of individual patient data.
@en
HER2 and TOP2A as predictive m ...... is of individual patient data.
@nl
P2093
P50
P921
P1433
P1476
HER2 and TOP2A as predictive m ...... is of individual patient data.
@en
P2093
Alison Munro
Chris J Twelves
Christopher Poole
Christos Sotiriou
David Cameron
Denis Larsimont
Fanny Piette
Frances P O'Malley
HER2/TOP2A Meta-analysis Study Group
Henning Mouridsen
P304
P356
10.1016/S1470-2045(11)70231-5
P577
2011-09-12T00:00:00Z